CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

budesonide/ glycopyrronium /formoterol fumarate

Last Updated: December 23, 2020
Result type: Reports
Project Number: SR0675-000
Product Line: Reimbursement Review

Generic Name: budesonide/ glycopyrronium /formoterol fumarate

Brand Name: (TBC)

Manufacturer: AstraZeneca Canada Inc.

Therapeutic Area: chronic obstructive pulmonary disease (COPD)

Indications: Budesonide/ glycopyrronium /formoterol fumarate is a combination of an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA), and a long-acting beta2-adrenergic agonist (LABA), indicated for the long-term maintenance treatment to reduce exacerbations of chronic obstructive pulmonary disease (COPD), and to relieve symptoms in patients with COPD, including chronic bronchitis and/or emphysema.

Manufacturer Requested Reimbursement Criteria1: ​For the long-term maintenance treatment to reduce exacerbations of COPD, and to relieve symptoms in patients with COPD, including chronic bronchitis and/or emphysema.

Submission Type: Initial

Project Status: Pending

Call for patient/clinician input open: December 23, 2020

Call for patient/clinician input closed: February 22, 2021

Anticipated Date: January 28, 2021

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback